Abstract Submission EHA18ABSSUB-3339 OUTCOMES OF INTERMEDIATE OR HIGH RISK MYELODYSPLASTIC SYNDROMES (MDS) PATIENTS POST AZACITIDINE AND/OR DECITABINE TREATMENT FAILURES WITH SGI-110, A NOVEL SECOND GENERATION HYPOMETHYLATING AGENT (HMA)
Results: Fifteen patients with Intermediate-1 (3), Intermediate-2 (5), High Risk (6) MDS and 1 with CMML, … were enrolled. All patients enrolled (100%) had prior treatment with decitabine and/or azacitidine; 87% had prior azacitidine, 53% had prior decitabine, and 40% had both azacitidine and decitabine as prior treatment2Responses were observed in 5 patients for an overall response rate of 33% with reported response duration of 28–224 days. Details of each of the 5 responders are shown in Table 1. The median bone marrow blast count at baseline for the responders was 16.5% while the non-responders were 5%. Median LINE1 demethylation in responders showed a decrease by -19.3% compared to -12.0% in non-responders.
Marrow CRs were reported in 2 of 8 patients who demonstrated LINE1 demethylation ≥ 10%. Currently the trial is enrolling treatment naïve MDS patients in the Phase 2 Dose Expansion Segment randomized to either 60 or 90 mg/m2 QDx5. Updated results from the Phase 2 will be presented.